Background
==========

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third most common cause of death from cancer worldwide \[[@B1],[@B2]\]. There are an estimated 626,000 to 1,000,000 new cases annually worldwide, with about half of these occurring in China alone \[[@B3],[@B4]\]. Despite advances in surgical and chemotherapeutic approaches, the survival rate of patients with HCC is as low as 20 to 50% at 5 years, even in early-stage HCC after radical resection \[[@B5],[@B6]\]. Recurrence after treatment remains one of the most important causes of poor long-term survival. Prediction of tumor carcinogenesis using molecular prognostic markers might aid in developing more effective therapeutic strategies and therefore result in better prognosis. However, to date, no identified molecular marker has shown unequivocal prognostic utility in HCC.

The Hedgehog (Hh) signaling pathway regulates body patterning, cell differentiation, and proliferation during embryonic development \[[@B7],[@B8]\]. In humans, the Hh signaling pathway consists of three ligands: Shh, Ihh, and Dhh, which can bind to the transmembrane receptor Patched 1 (Ptch1). Upon ligand binding to Ptch1, Smoothened (Smo) is released, signals are transduced to the nucleus, and these converge on three Gli zinc finger transcription factors: Gli1, Gli2, and Gli3 \[[@B9]\]. Aberrant activation of the Hh pathway has recently been reported in various human cancers, including basal cell carcinoma, gastrointestinal malignancies, and breast, prostate, pancreatic, and lung cancers \[[@B10]-[@B16]\]. In addition, the Hh pathway cascade cross-talks with the WNT, EGF/FGF, and TGF-β/Activin/Nodal/BMP signaling cascades, which are implicated in epithelial-to-mesenchymal transition (EMT) through repression of E-cadherin and activation of N-cadherin, therefore, the Hh pathway is associated with invasion and metastasis of tumors \[[@B17]\].

Previous studies have shown that components of the Hh pathway are indicators for poor survival in bladder cancer, oral and esophageal squamous cell carcinoma, and ovarian, colon and breast cancers \[[@B18]-[@B23]\]. Of the three Gli transcriptional factors, Gli2 is a strong positive activator of downstream target genes, and it can induce Gli1 expression independent of Hh signaling \[[@B24]\]. The Gli2 protein has been reported to have high expression levels in HCC cell lines and human HCC tissues \[[@B25]-[@B28]\]. Our previous work showed that small hairpin (sh)RNA-mediated silencing of the Gli2 gene inhibits proliferation by inducing cell-cycle arrest at G1 phase in the HCC SMMC-7721 cell line. Moreover, knockdown of Gli2 enhanced SMMC-7721 to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell apoptosis via downregulation of c-FLIP and Bcl-2, consequently leading to induction of caspase-8 or caspase-9 dependent apoptosis pathway \[[@B29]\]. However, there have been few clinical reports investigating the relationship between Gli2 protein expression and the postoperative survival of patients with HCC, or whether Gli2 is realated to induction of EMT.

In the current study, we examined expression of Gli2 protein in HCC tissue using immunohistochemistry. We also evaluated the relationship of this expression with the clinical characteristics, expression of E-cadherin, N-cadherin, and vimentin, and prognosis to determine whether the level of Gli2 expression could be used to predict prognosis in patients with HCC after radical hepatectomy.

Methods
=======

Ethics approval
---------------

The study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical College with the following reference number: GY20080216302. Each patient provided written informed consent before hepatectomy.

Patients and liver specimens
----------------------------

Samples of primary HCC tissues (n = 68) and corresponding paraneoplastic liver tissue (PLT, taken at 20 mm distance from the tumor margin) were obtained from patients (53 men, 15 women, median age 55 years; range 33--78 years) who underwent curative resection at the Second Affiliated Hospital of Guangzhou Medical College (Guangzhou, China) between February 2004 and July 2007. The diagnosis was confirmed by histologic examination. Curative resection was defined as removal of all recognizable tumor tissue with a clear microscopic margin. Specimens were obtained immediately after surgical resection. The patients were not pretreated with radiotherapy or chemotherapy before surgery. The control tissues were 20 samples of normal liver tissue (NLT), which were acquired from patients who had undergone surgery for liver trauma. All specimens were fixed in 10% formalin, and embedded in paraffin wax for immunohistochemical analysis.

The clinicopathologic variables are shown in Table [1](#T1){ref-type="table"}. Tumor size ranged from 32 to 193 mm, with a median of 65 mm. The TNM (tumor, node, metastasis) stage was determined using the American Joint Committee on Cancer/International Union Against Cancer tumor classification system, with 45 patients classified as I or II and 23 as III or IV. Tumor differentiation was classified as follows: 16 tumors were well differentiated, 39 were moderately differentiated, and 13 cases were poorly differentiated.

###### 

Clinicopathologic characteristics of 68 patients with hepatocellular carcinoma (HCC)

  **Variable**            **Patients, n**
  ----------------------- -----------------
  Gender                   
  Male                    53
  Female                  15
  Age, years               
  ≤60                     43
  \>60                    25
  Virus infection          
  HBV                     58
  HCV                     2
  None                    8
  AFP, ng/ml               
  ≤200                    28
  \>200                   40
  Cirrhosis                
  Present                 48
  Absent                  20
  Tumor size, mm           
  ≤50                     18
  \>50                    50
  TNM stage                
  I                       12
  II                      33
  III                     20
  IV                      3
  Tumor differentiation    
  Well                    16
  Moderate                39
  Poor                    13
  Tumor number             
  Solitary                54
  Multiple                14
  Tumor encapsulation      
  Intact                  39
  Absent or not intact    29
  Vascular invasion        
  Present                 29
  Absent                  39

Abbreviations: AFP, alpha fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; TMN, tumor, node, metastasis.

Immunohistochemistry
--------------------

Formalin-fixed, paraffin wax-embedded tissue specimens were obtained. Serial sections 4 μm thick were prepared from each sample, then some sections were stained with hematoxylin and eosin for histologic diagnoses of tumor and non-tumor, while other sections were stained for Gli2 using the streptavidin--biotin horseradish peroxidase complex method. For the latter, the tissue sections were dewaxed, rehydrated with a xylene and graded alcohol series, and then incubated in 3% hydrogen peroxide for 10 minutes to block endogenous peroxidase activity. Optimal antigen retrieval was carried out in citrate buffer (pH 6.0) for 10 minutes in a microwave oven to enhance the immunoreactivity, and then sections were incubated in 10% blocking serum for 30 minutes at 37°C to reduce nonspecific binding. Primary anti-Gli2 polyclonal antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) were diluted 1:100, and incubated with the sections at 4°C overnight. Subsequently, the secondary antibodies (biotinylated goat anti-rabbit immunoglobulin) and streptavidin peroxidase complex reagent were applied. Finally, the visualization signal was developed with diaminobenzidine (DAB), and the slides were counterstained with hematoxylin. Two investigators blinded to the clinical information evaluated each stained section.

The Gli2 reaction for Gli2 was graded according to the staining intensity (0, 1+, 2+, and 3+). The percentages of Gli2--positive cells were also scored on a four-point scale as 0 (0%), 1 (1 to 33%), 2 (34 to 66%), and 3 (67 to 100%). The sum of the intensity and percentage scores was used as the final Gli2 protein staining score. The staining pattern was defined as follows: 0, negative; 1 to 2, weak; 3 to 4, moderate; 5 to 6, strong \[[@B30],[@B31]\]. For statistical analyses, scores of 0 to 2 were considered 'low expression' and scores of 3 to 6 were considered 'high expression'.

Follow-up
---------

The follow-up period was defined as the interval from the date of operation to that of the last visit or the patient's death. Deaths from other causes were treated as censored cases. After discharge, patients were followed up every 3 months during the first 2 years and every 6 months thereafter by clinical examination, including measurement of alpha fetoprotein, ultrasonography and computed tomography (CT). Times of tumor recurrence were recorded, based on the time of recurrences from the date of hepatectomy, they were classified as early (≤1 year) and late (\>1 year) recurrences. Patients who developed recurrence were treated with radiofrequency ablation, percutaneous ethanol injection, or transcatheter arterial chemoembolization, or with re-resection when necessary. Disease-free survival (DFS) was defined as the interval from the operation date to recurrence, and overall survival (OS) was defined as the interval between the operation date and death. Follow-up was performed using email and telephone.

Statistical analysis
--------------------

The χ^2^ text or Fisher's exact test was used to analyze the relationship between Gli2 expression and the clinicopathologic characteristics. DFS and OS were calculated using the Kaplan-Meier method, and differences were assessed using the log-rank test. The Cox proportional hazard regression model was used to examine associations between the various prognostic factors and survival. For all tests, a value of *P* \< 0.05 was considered significant. All statistics were calculated using SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA).

Results
=======

Expression of Gli2
------------------

Follow-up data were obtained for all 68 patients. All patients were followed up until November 2010. The follow-up time ranged from 6 to 79 months, with a median follow-up time of 52 months.

The immunohistochemical staining identified the Gli2 location in the cytoplasm and/or nucleus of tumor cells, mainly in the cytoplasm. Gli2 expression in NLT from hemangiomas and PLT were negative or weakly positive (Figure [1](#F1){ref-type="fig"}A,B,E,F), and mainly moderately or strongly positive in HCC (Figure [1](#F1){ref-type="fig"}C,D,G,H). Overall, high expression of Gli2 was recorded in 63.2% (43/68), 11.8% (8/68), and 10% (2/20) of the biopsies in HCC, PLT, and NLT samples, respectively. There were significant differences for Gli2 staining between NL and HCC (*P*\<0.05), and between PLT and HCC (*P*\<0.05), but there was no significant difference between NL and PLT (*P*\>0.05).

![**Representative images of Gli2 immunohistochemical staining in human normal liver tissue (NLT), paraneoplastic liver tissue (PLT), and HCC.** (**A,E**) NLT with negative Gli2 expression. (**B,F**) PLT with week Gli2 expression. (**C,G**) HCC with moderate Gli2 expression. (**D,H**) HCC with strong Gli2 expression. Original magnification (A-D) × 200 for E-H × 400.](1477-7819-11-25-1){#F1}

Immunohistochemistry analysis of Gli2 expression and its relationship with clinicopathologic characteristics
------------------------------------------------------------------------------------------------------------

Correlation between the expression levels of Gli2 in HCC and various clinicopathologic variables are summarized in Table [2](#T2){ref-type="table"}. A high expression level for Gli2 protein was significantly correlated with tumor differentiation, encapsulation, vascular invasion, early recurrence, and intra-hepatic metastasis (*P*\<0.05). There was no significant correlation between Gli2 expression and gender, age, hepatitis virus serology, AFP level, cirrhosis, tumor size, TNM stage, or number of tumors (*P*\>0.05).

###### 

Correlation between Gli2 expression and clinicopathologic characteristics in HCC

  **Characteristics**        **Gli2 expression**   **χ**^**2**^   ***P*value**   
  -------------------------- --------------------- -------------- -------------- ------------
  Gender                                                                         
  Male                       33                    20             0.097          0.755
  Female                     10                    5                              
  Age, years                                                                     
  ≤60                        29                    14             0.890          0.345
  \>60                       14                    11                             
  Virus infection                                                                
  HBV                        35                    23             0.698          0.403
  HCV                        2                     0                              
  None                       6                     2                              
  AFP (ng/ml)                                                                    
  ≤200                       20                    8              1.374          0.241
  \>200                      23                    17                             
  Cirrhosis                                                                      
  Present                    30                    18             0.038          0.846
  Absent                     13                    7                              
  Tumor size, mm                                                                 
  ≤50                        26                    13             0.837          0.360
  \>50                       15                    12                             
  TNM stage                                                                      
  I or II                    25                    20             3.375          0.066
  III or IV                  18                    5                              
  Tumor differentiation                                                          
  Well                       6                     10             6.591          0.037 ^\*^
  Moderate                   28                    11                             
  Poor                       9                     4                              
  Tumor number                                                                   
  Solitary                   32                    22             1.784          0.182
  Multiple                   11                    3                              
  Tumor encapsulation                                                            
  Intact                     11                    15             7.930          0.005 ^\*^
  Absent or not intact       32                    10                             
  Vascular invasion                                                              
  Present                    23                    6              5.620          0.018 ^\*^
  Absent                     20                    19                             
  Early recurrence                                                               
  Yes                        25                    8              4.324          0.038 ^\*^
  No                         18                    17                             
  Intra-hepatic metastasis                                                       
  Present                    16                    5              4.997          0.025 ^\*^
  Absent                     17                    20                             

Variables are presented as number and tested by χ^2^ or Fisher's exact test.

\* *P* \< 0.05.

Association between E-cadherin, N-cadherin, vimentin, and Gli2 expression in hepatocellular carcinoma
-----------------------------------------------------------------------------------------------------

Given the role of Hedgehog signaling in inducing EMT through multiple regulators, such as Snail, ZEB1, ZEB2, Twist1, Twist2, and FOXC2, \[[@B17]\] we analyzed the relationship between Gli2 expression and that of E-cadherin, N-cadherin and vimentin in the 68 HCC samples. Expression of Gli2 was negatively correlated with E-cadherin, and positively correlated with N-cadherin and vimentin. Tissue with high expression levels for Gli2 also had high expression levels for N-cadherin (*r* = −0.505, *P* \< 0.05) and vimentin (*r* = −0.468, *P* \< 0.05), but low expression of E-cadherin (*r* = −0.302, *P* \< 0.05) d Representative images are shown in Figure [2](#F2){ref-type="fig"} and the statistical results are listed in Table [3](#T3){ref-type="table"}.

![**Immunohistochemical staining of Gli2, E-cadherin, N-cadherin, and vimentin in two representative hepatocellular carcinoma (HCC) cases.** (**a,c,d,e)** Patient 1. Expression of Gli2, N-cadherin and vimentin was positive, whereas E-cadherin was negative. **(b,d,f,h)** Patient 2. Expression of Gli2, N-cadherin and vimentin was negative, whereas E-cadherin expression was positive. Original magnification × 400.](1477-7819-11-25-2){#F2}

###### 

Association between expression of Gli2 and expressin of E-cadherin, N-cadherin and vimentin in patients with hepatocellular carcinoma

  **Expression level**   **Gli2 expression**   **χ**^**2**^   ***P*value**   **Association coefficient (*r*)**   
  ---------------------- --------------------- -------------- -------------- ----------------------------------- --------
  E-cadherin                                                                                                     
  High                   12                    31             6.801          0.009^\*^                           −0.302
  Low                    15                    10                                                                 
  Vimentin                                                                                                       
  High                   35                    8              6.801          0.009^\*^                           0.468
  Low                    7                     18                                                                 
  N-cadherin                                                                                                     
  High                   37                    6              23.324         0.001^\*^                           −0.505
  Low                    7                     18                                                                 

\* *P* \< 0.05.

Survival analysis
-----------------

We assessed the Kaplan-Meier estimates for the group with high Gli2 expression and the group with low Gli2 expression. Our results indicated that the median OS for the two groups were 17 and 58 months, respectively. The log-rank test showed as significant difference between the two survival curves; the OS rate of the group with high Gli2 expression was lower than that of the group with low Gli2 expression (*P* \< 0.05). Similarly, the median DFS time for the two groups was 8 and 30 months, respectively, and patients with high Gli2 expression of Gli2 had a significantly shorter DFS compared with the patients with low Gli2 expression (*P* \< 0.05) (Figure [3](#F3){ref-type="fig"}).

![**Overall survival (OS) curves of patients with hepatocellular carcinoma (HCC) undergoing hepatectomy were compared between the groups with high and low expression of Gli2.** (**A**) OS; (**B**) disease-free survival.](1477-7819-11-25-3){#F3}

Univariate and multivariate analyses for the prognostic value of Gli2 expression
--------------------------------------------------------------------------------

In univariate analysis, the factors significantly associated with OS were tumor size, TNM stage, differentiation, tumor encapsulation, vascular invasion, and Gli2 expression, and those significantly associated with DFS were tumor size, tumor encapsulation, vascular invasion, and Gli2 expression (Table [4](#T4){ref-type="table"}). Furthermore, multivariate Cox proportional hazards regression analysis indicated that in patients with HCC, tumor size, vascular invasion, and Gli2 expression were independent prognostic factors for OS, while tumor encapsulation, vascular invasion, and Gli2 expression were independent predictors for DFS (*P* \< 0.05) (Table [5](#T5){ref-type="table"}).

###### 

Univariate analysis of factors associated with overall survival (OS) and disease-free survival (DFS) of 68 patients with hepatocellular carcinoma

  **Factor**                                                 ***P*value**   
  ---------------------------------------------------------- -------------- ------------
  Gender (male versus female)                                0.564          0.867
  Age (≤60 versus \>60 years)                                0.430          0.682
  Virus (HBV versus HCV and none)                            0.410          0.247
  AFP (≤200 versus \>200 ng/ml)                              0.909          0.626
  Cirrhosis (absent versus present)                          0.313          0.551
  Tumor size (≤50 versus \>50 mm)                            0.005 ^\*^     0.001 ^\*^
  TNM stage (I to II versus III to IV)                       0.034 ^\*^     0.056
  Differentiation (well and moderate versus poor)            0.011 ^\*^     0.110
  Tumor number (solitary versus multiple)                    0.401          0.741
  Tumor encapsulation (intact versus absent or not intact)   0.011 ^\*^     0.009 ^\*^
  Vascular invasion (absent versus present)                  0.003 ^\*^     0.001 ^\*^
  Gli2 expression (low versus high)                          0.005 ^\*^     0.017 ^\*^

Abbreviations: AFP, alpha fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; TMN, tumor, node, metastasis.

\* *P* \< 0.05.

###### 

Multivariate Cox regression analysis

  **Factor**              ***P*value**   **Hazard ratio**   **95% Confidence interval**
  ----------------------- -------------- ------------------ -----------------------------
  Overall survival                                           
  Tumor size              0.002^\*^      2.509              1.414 to 4.454
  TNM stage               NS             ---                ---
  Differentiation         NS             ---                ---
  Tumor encapsulation     NS             ---                ---
  Vascular invasion       0.004^\*^      2.305              1.304 to 4.073
  Gli2 expression         0.007^\*^      2.239              1.244 to 4.028
  Disease-free survival                                      
  Tumor size              NS             ---                ---
  Tumor encapsulation     0.001^\*^      2.763              1.534 to 4.977
  Vascular invasion       0.002^\*^      2.516              1.397 to 4.533
  Gli2 expression         0.042^\*^      1.917              1.025 to 3.584

Abbreviations: AFP, alpha fetoprotein; NS, not significant.

\* *P* \< 0.05.

Discussion
==========

Gli2, a transcription factor of the Hh pathway, regulates expression of downstream target genes, including Gli1, Bcl-2, c-FLIP, cyclin D1, c-Myc and vascular endothelial growth factor (VEGF) \[[@B32]-[@B35]\], which has previously been implicated in the development of various human tumors, such as medulloblastomas, basal cell carcinoma, prostate and breast cancer, and HCC \[[@B28],[@B36]-[@B38]\], Gli2 was reportedly overexpressed and related to poor survival of patients with pediatric medulloblastoma. Although high expression levels of the Gli2 protein has been reported in HCC cell lines and tissues \[[@B25],[@B26],[@B39]\], the association between Gli2 expression and prognosis in patients with HCC has not been elucidated. To analyze the role of Gli2 in HCC, we carried out immunohistochemical staining and found higher levels of Gli2 protein in HCC tissues compared with PLT and NLT.

Analyzing the association of Gli2 expression with pathologic characteristics in 68 patients with HCC identified a significant correlation of Gli2 expression with tumor differentiation, encapsulation, vascular invasion, early recurrence, and intra-hepatic metastasis. Kaplan-Meier analysis showed that patients with HCC who had high expression of Gli2 had significantly worse prognosis than those with low expression, both for OS and DFS. Multivariate analysis showed that Gli2 was an independent prognostic factor for both recurrence and survival in patients with HCC after hepatectomy. Meanwhile, tumor size and vascular invasion were also independent prognostic factors for OS, while tumor encapsulation and vascular invasion were independent prognostic factors for DFS. Therefore, the level of protein expression of Gli2, a novel molecular biomarker, may be a powerful prognostic indicator for recurrence and survival of patients with HCC.

Our results showed that high expression of Gli2 was associated with vascular invasion, early recurrence, and intra-hepatic metastasis in patients with HCC, suggesting that overexpression of Gli2 contributes to progression of HCC. Furthermore, the immunohistochemical results showed a significantly negative correlation between Gli2 and E-cadherin expression and a significantly positive correlation between Gli2 expression and both vimentin and N-cadherin expression. We speculate that Gli2 could play an important role in invasion and metastasis of HCC by inducing EMT.

In previous studies, EMT was characterized by decreased cell adhesion and increased motility, which was accompanied by downregulation of E-cadherin and upregulation of vimentin and N-cadherin \[[@B40],[@B41]\]. Zheng *et al*. found that Gli1 protein expression was positively correlated with Shh and S100a4, and negatively correlated with E-cadherin \[[@B42]\]. EMT is regulated by several transcription factors, including Snail, ZEB1, ZEB2, Twist1, and Twist2, each of which bind to the E-cadherin promoter region and repress its transcription \[[@B43]-[@B49]\]. The Hh pathway induces JAG2 upregulation for Notch-CSL-mediated Snal1 upregulation, and also induces transforming growth factor (TGF)-β secretion for ZEB1 and ZEB2 upregulation via the TGF-β receptor and nuclear factor (NF)-κB. TGF-β-mediated downregulation of the microRNAs R-141, 200a, 200b, 200c, 205, and 429 results in upregulation of the ZEB1 and ZEB2 proteins. Activation of Hh signaling indirectly leads to EMT through Notch, TGF-β signaling cascades, and regulatory networks of microRNA \[[@B17]\]. Recently, Alexaki *et al*. investigated the role of Gli2 in the invasion and metastasis of melanoma and found that increased expression of Gli2 was associated in melanoma cell lines with loss of E-cadherin expression and increased capacity to invade a protein gel (Matrigel) and to form bone metastases in mice \[[@B50]\]. Taken together, these results indicate that Gli2 might lead to the increased early recurrence and development of intra-hepatic metastases of HCC by induction of EMT.

Conclusion
==========

Our current findings indicate for the first time that the expression level of Gli2 is high in HCC tissue, and this high expression shows a significant association with poor clinical outcome after hepatectomy and a more aggressive tumor phenotype because it induces EMT changes. However, further studies are needed to investigate the biochemical mechanisms by which Gli2 induces EMT of HCC.
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